Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics

Tae Min You, Kang Hee Lee, Soo Hyeon Lee, Wonse Park

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.

Original languageEnglish
Article number1260
Pages (from-to)548-553
Number of pages6
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Issue number5
Publication statusPublished - 2015 Nov

Bibliographical note

Funding Information:
This research was supported by a Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-2013 R1 A1 A 1009513).

Publisher Copyright:
© 2015 Elsevier Inc.

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Dentistry (miscellaneous)
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics'. Together they form a unique fingerprint.

Cite this